131 related articles for article (PubMed ID: 37548597)
1. Dose-Dependent Effect of Phenothiazines as Dynamin II Inhibitors on the Uptake of PEGylated Liposomes by Endocytic Cells and In Vivo Pharmacokinetics of PEGylated Liposomal Doxorubicin in Rats.
Subasic CN; Butcher NJ; Simpson F; Minchin RF; Kaminskas LM
Mol Pharm; 2023 Sep; 20(9):4468-4477. PubMed ID: 37548597
[TBL] [Abstract][Full Text] [Related]
2. A PEGylated liposomal formulation of prochlorperazine that limits brain exposure but retains dynamin II activity: A potential adjuvant therapy for cancer patients receiving chemotherapeutic mAbs.
Subasic CN; Simpson F; Minchin RF; Kaminskas LM
Nanomedicine; 2024 Feb; 56():102733. PubMed ID: 38199450
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
4. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
5. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
[TBL] [Abstract][Full Text] [Related]
6. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
7. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L; Ceruti M; Dosio F
Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
[TBL] [Abstract][Full Text] [Related]
8. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
9. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction.
Subasic CN; Kuilamu E; Cowin G; Minchin RF; Kaminskas LM
J Control Release; 2021 Sep; 337():71-80. PubMed ID: 34245788
[TBL] [Abstract][Full Text] [Related]
11. Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics.
Børresen B; Henriksen JR; Clergeaud G; Jørgensen JS; Melander F; Elema DR; Szebeni J; Engelholm SA; Kristensen AT; Kjær A; Andresen TL; Hansen AE
ACS Nano; 2018 Nov; 12(11):11386-11398. PubMed ID: 30372038
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.
Sridhar KS; Krishan A; Samy TS; Duncan RC; Sauerteig A; McPhee GV; Auguste ME; Benedetto PW
Cancer Chemother Pharmacol; 1994; 34(5):377-84. PubMed ID: 8070004
[TBL] [Abstract][Full Text] [Related]
13. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
14. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
Bavli Y; Winkler I; Chen BM; Roffler S; Cohen R; Szebeni J; Barenholz Y
J Control Release; 2019 Jul; 306():138-148. PubMed ID: 31176656
[TBL] [Abstract][Full Text] [Related]
15. Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis.
Daniel JA; Chau N; Abdel-Hamid MK; Hu L; von Kleist L; Whiting A; Krishnan S; Maamary P; Joseph SR; Simpson F; Haucke V; McCluskey A; Robinson PJ
Traffic; 2015 Jun; 16(6):635-54. PubMed ID: 25693808
[TBL] [Abstract][Full Text] [Related]
16. PEGylated Liposomes Accumulate in the Areas Relevant to Skin Toxicities
Li Y; Lofchy L; Wang G; Gaikwad H; Fujita M; Simberg D
ACS Nano; 2022 Apr; 16(4):6349-6358. PubMed ID: 35343675
[TBL] [Abstract][Full Text] [Related]
17. Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.
Sridhar KS; Krishan A; Samy TS; Sauerteig A; Wellham LL; McPhee G; Duncan RC; Anac SY; Ardalan B; Benedetto PW
Cancer Chemother Pharmacol; 1993; 31(6):423-30. PubMed ID: 8453681
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
20. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug.
Lu WL; Qi XR; Zhang Q; Li RY; Wang GL; Zhang RJ; Wei SL
J Pharmacol Sci; 2004 Jul; 95(3):381-9. PubMed ID: 15272215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
